Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Alfonso Valle
Januzzi JL, Prescott MF, Butler J, et al. Association...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Alfonso Valle
Januzzi JL, Prescott MF, Butler J, et al. Association...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in ...
Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF
- SAC/VAL en pacientes con ICrFEVI, disminuye cifras de NT-proBNP, ...
Upcoming SlideShare
Loading in …5
×

PROVE HF Study

354 views

Published on

El Dr. Alfonso Valle Muñoz resume los resultados obtenidos en el estudio presentado en ESC Congress 2019.

Published in: Health & Medicine
  • Be the first to comment

PROVE HF Study

  1. 1. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  2. 2. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Alfonso Valle Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  3. 3. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  4. 4. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Alfonso Valle Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  5. 5. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821 OBJETIVO PRIMARIO Asociación entre los cambios de NT-proBNP y remodelado (VTDVI, VTDVI, FEVI, Vol AI) a los 12 meses OBJETIVO SECUNDARIOS Asociación entre los cambios de NT-proBNP y remodelado (VTDVI, VTDVI, FEVI, Vol AI) a los 6 meses Asociación entre los cambios de NT-proBNP y calidad de vida (KCCQ-23) a los 12 meses OBJETIVO EXPLORATORIOS Cambio de otros biomarcadores y su relación pronóstica Asociación entre los cambios de biomarcadores, remodelado en eco y eventos CV a los 12m (muerte total; muerte CV, MS, MnoS, HHF, ICA)
  6. 6. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  7. 7. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  8. 8. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  9. 9. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  10. 10. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  11. 11. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  12. 12. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  13. 13. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  14. 14. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  15. 15. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. Published online September 02, 2019. doi:10.1001/jama.2019.12821
  16. 16. Alfonso Valle MuñozAlfonso Valle MuñozEstudio PROVE HF - SAC/VAL en pacientes con ICrFEVI, disminuye cifras de NT-proBNP, y se asocia de manera significativa con el remodelado inverso del VI - En el global de la muestra la mejoría de la FEVI a 12 meses es de 9.4%. Implicaciones pronósticas y de manejo de pacientes - El grado de remodelado explica como SAC/VAL reduce morbilidad y mortalidad en pacientes con ICrFEVI (PARADIGM-HF) - La mayor reducción de NT-proBNP ocurre principalmente en las 2 primeras semanas de tratamiento - En pacientes NAIVE/novo la mejora de la FEVI 12.8% - Mantiene respuesta en pacientes con péptidos bajos y dosis baja/media de SAC/VAL

×